ReviewFrontiers in oncology2021
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and Safety of Treatments for Early-Stage Merkel Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies.Cancer medicine · 2025Pooled it
- [Immunotherapy of cutaneous neoplasms].Magyar onkologia · 2025Review
- Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges.Head & neck · 2025Review
- Immune Checkpoint Inhibitors in Merkel Cell Carcinoma of the Skin: A 2025 Comprehensive Review.Cancers · 2025Review
- Immune Checkpoint Inhibitor-Related Dysautonomia in Merkel Cell Carcinoma: A Case Report.Cancer reports (Hoboken, N.J.) · 2025Review
- What is the predominant etiological factor for Merkel cell carcinoma in Turkey: viral infection or sun exposure?BMC cancer · 2025Article
- An Unusual Complete Response to Immunotherapy in a Locoregional Recurrent Merkel Cell Carcinoma.Cureus · 2025Article
- Chemoreactive 2,5-Diketopiperazines from aJournal of natural products · 2024Article
- Systematic evaluation of Merkel cell carcinoma clinical practice guidelines using the AGREE II instrument.Archives of dermatological research · 2024Article
- Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance.The Journal of dermatology · 2024Article
- Skin Investigation Network of Canada (SkIN Canada) Priority Setting Initiative ranks the top 10 evidence uncertainties for Merkel cell carcinoma.The British journal of dermatology · 2024Article
- Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution.Cancer medicine · 2023Article
- Multidisciplinary Treatment of Merkel Cell Carcinoma of the Extremities: Outcomes and Factors Associated with Poor Survival in Nodal Disease.Current oncology (Toronto, Ont.) · 2023Article
- Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case-Control Study and Literature Review.Cancers · 2022Article
- Seroprevalence of Four Polyomaviruses Linked to Dermatological Diseases: New Findings and a Comprehensive Analysis.Viruses · 2022Article
- Intestinal obstruction due to small intestinal metastasis from primary Merkel cell carcinoma of the gluteal region.Ecancermedicalscience · 2022Article
- Prognostic Value of Radiotherapy and Chemotherapy in Stage I-III Merkel Cell Carcinoma.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is a rare, highly aggressive, neuroendocrine cutaneous tumor. The incidence of MCC is growing worldwide, and the disease-related mortality is about three-fold higher than melanoma. Since a few years ago, very little has been known about this disease, and chemotherapy has been the standard of care. Nowadays, new discoveries about the pathophysiology of this neoplasm and the introduction of immunotherapy allowed to completely rewrite the history of these patients. In this review, we provide a summary of the most important changes in the management of Merkel cell carcinoma, with a focus on immunotherapy and a landscape of future treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.